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 “Obsessed is just a word the lazy use to describe the dedicated.” 
 
Russell Warren 
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 1. SUMMARY 
 
Growth of an organ during development and during adaptation in the adult can be controlled by 
alterations either in the number or the size of cells. The two mechanisms are fundamentally different 
and require distinct regulation. Rapamycin is a cell growth inhibitor used to treat a number of clinical 
indications including graft rejection and cancer. The molecular target of rapamycin is a Ser/Thr kinase, 
called TOR in yeast or mTOR in mammals. The evolutionarily conserved TOR pathway controls key 
aspects of cellular growth and metabolism. Among these are protein synthesis, ribosome biogenesis, 
nutrient transport and processing, autophagy and mitochondrial function. mTOR assembles into two 
distinct multiprotein complexes, termed mTORC1 and mTORC2. mTORC1 consists of raptor 
(regulatory associated protein of mTOR), mLST8 (mammalian lethal with SEC13 protein 8) and 
mTOR, and is sensitive to rapamycin. mTORC2 consists of rictor (rapamycin insensitive companion of 
mTOR), mSIN1, mLST8 (mammalian stress activated protein kinase interacting protein 1) and mTOR. 
As mTORC1 controls cell growth, it has also been implicated in the control of muscle mass. A vast 
array of genetic and pharmacological studies using rodent models supports this view. In contrast to the 
role of mTOR in growth, its metabolic readouts in skeletal muscle are poorly characterized. Little is 
also known of the function of rapamycin-insensitive mTORC2 whose primary readouts are thought to 
be the organization of the actin cytoskeleton. Recently, mTORC2 has also been proposed to be the 
essential kinase that phosphorylates PKB/AKT on Ser473.  
 
To circumvent the early embryonic lethality of mice deficient for raptor (i.e. mTORC1) or rictor (i.e. 
mTORC2), we generated mice with floxed raptor or rictor alleles. Here we describe the phenotype of 
mice that lack functional mTORC1, mTORC2, or both complexes, specifically in skeletal muscle. We 
find that deletion of rictor does not cause an overt muscle phenotype. In contrast, raptor-deficient 
muscles manifest signs of atrophy and become progressively dystrophic. These muscles also display 
fundamental metabolic changes which involve impaired mitochondrial function. Furthermore, muscles 
display properties of fast-twitch, glycolytic skeletal muscle, but exhibit structural features and 
contraction properties indicative of slow-twitch, oxidative muscle fibers. These changes are either due 
to impaired activation of direct downstream substrates of mTORC1 or due to loss of negative feedback 
regulation of upstream components of the signaling pathway. Interestingly, this increased upstream 
signaling causes sustained hyperactivation of PKB/AKT, which is independent of mTORC2 kinase 
activity. Taken together, we provide unprecedented evidence for a crucial role of mTORC1 in the 
regulation of fundamental aspects of metabolism in a specific tissue. Furthermore we show that in the 
absence of negative feedback regulation from mTORC1 downstream components, mTORC2 is 
dispensable for PKB/AKT activation. 
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1.1 List of abbreviations 
 
4E-BP1 eIF4E binding protein 1 
AMPK AMP activated protein kinase 
Atg atrogenes 
ATM ataxia telangiectasia mutated gene product  
COX IV cytochrome c oxidase IV 
DmKO double muscle knockout mice (raptor & rictor) 
DNK-PK doublestranded DNA dependent protein kinase 
EDL extensor digitorum longus (muscle) 
eNOS endothelial nitric oxide synthase 
ERK extracellular regulated protein kinase 
FOXO forkhead transcription factor 
GLUT4 glucose transporter 4 
GP glycogen phosphorylase 
GS glycogen synthase 
GSK-3 glycogen synthase kinase 3 
GTPases small guanosine triphosphatases 
HSA human skeletal actin 
IGF-R IGF receptor  
IKKβ inhibitory κB kinase β 
ILK integrin linked kinase 
Inuslin-R insulin receptor  
MAFbx  muscle atrophy F-box / Atrogin-1 
MDM2 murine double minute 2  
Mef2A myocyte enhancer factor 2A 
MGF mechano growth factor 
MK2 MAPK activated protein kinase 2 
mLST8 mammalian lethal with SEC13 protein 8  
mSin1 mammalian stress activated protein kinase interacting protein 1 
mTOR mammalian target of rapamycin 
mTORC1/2 mTOR Complex 1/2 
MuRF-1 Muscle RING finger 1  
NADH-TR NADH tetrazolium staining 
NEK6 NIMA related kinase 6 
NFAT nuclear factor of activated T cells 
OXPHOS oxidative phosphorylation 
PAS periodic acid schiff staining 
PDK1/2 phosphoinositide dependent kinase 1/2 
PGC-1α peroxisome proliferator activated receptor γ (PPARγ) coactivator 1 
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PI3K phosphoinositide 3 kinase 
PIP3 phosphatidylinositol 3,4,5 trisphosphate  
PKB/AKT protein kinase B 
PKC protein kinase C 
PRAS40 prolinerich Akt substrate 40  
PRR5 / Protor proline rich protein 5 / protein observed with rictor 
PRR5L PRR5-like protein 
RAmKO raptor muscle knockout mice 
raptor regulatory associated protein of mTOR 
REDD1 protein regulated in development and DNA damage response 1 
Rheb Ras homolog enriched in brain 
rictor  rapamycin insensitive companion of mTOR 
RImKO rictor muscle knockout mice 
RTK receptor tyrosine kinase  
S6 40S ribosomal protein S6 
S6K S6 kinase 
slMHC slow myosin heavy chain 
slTnI slow isoform of troponin I 
slTnT slow isoform of troponin T  
TNFR  tumor necrosis factor receptor 
TNFα tumor necrosis factor α 
TSC1/2 tuberous sclerosis complex 1/2 
YY1  yin yang 1 
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 2. INTRODUCTION 
2.1. Catching a glimpse of mTOR and its role in skeletal muscle 
Loss of muscle mass can be due to many pathological conditions such as muscle dystrophy, AIDS, 
sepsis, burns, injuries or cancer. The wasting of muscle is not only a side effect of the primary disease 
but often contributes to morbidity. For example, cachexia is responsible for the deaths of ~22% of 
cancer patients [1]. Moreover, loss of muscle in the elderly contributes substantially to the loss of 
"quality of life" and the overall health costs [2]. Similarly, muscle contributes strongly to the metabolism 
of the entire body and it is well established that muscle exercise positively influences the outcome of 
metabolic disorders such as diabetes [3]. Although the medical need to treat muscle loss is obvious, 
still little is known about the molecular 
mechanisms involved in regulating the 
plasticity of adult skeletal muscle. 
 
2.1.1. mTOR mediated muscle growth 
 
In the past years, evidence has 
accumulated that the mTOR signaling 
pathway is likely to be one of the effector 
pathways involved in controlling 
postnatal muscle plasticity. The scientific 
basis for this role of mTOR is the finding 
that both upstream and downstream 
components of mTOR have been shown 
to control muscle mass in rodents. For 
example, the main activators of mTOR, 
insulin-like growth factor-1 (IGF-1) and 
protein kinase B (PKB; also called AKT) 
are both involved in this process. 
Transgenic mice that overexpress IGF-1 
in skeletal muscle have bigger muscles 
and mice deficient in PKB/AKT have smaller organs including muscle fibers [4, 5]. Furthermore, 
constitutively active forms of PKB/AKT can induce profound muscle hypertrophy in mice [6-8]. 
Interestingly, pharmacologic blockade of mTOR prevents PKB/AKT mediated muscle hypertrophy in 
these animals [6]. Beyond the evidence from studies on IGF-1 or PKB/AKT, overexpression of TSC1, 
an upstream inhibitor of mTOR, and inactivation of the mTOR downstream target S6K, cause muscle 
atrophy in mice [9, 10]. Furthermore, pharmacological inhibition of mTOR prevents hypertrophy of 
soleus muscles during synergistic ablation and recovery from muscle atrophy after hind limb 
FIGURE 1. Proposed cellular functions of mTOR.  
mTOR integrates positive environmental cues such as growth 
factors and nutrients and propagates anabolic signals into the 
cell. Catabolic processes are blocked whereas protein 
anabolism is fostered. Furthermore energy generation via 
mitochondria is facilitated by the activation of mTOR.  
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suspension [8]. In summary, genetic and pharmacologic studies in rodents point out that mTOR has a 
crucial role in the regulation of skeletal muscle mass. Nevertheless, because of early embryonic 
lethality, direct evidence in form of a mTOR knockout mouse is still missing [11-13]. 
 
Next to experimental evidence from studies with rodents, also in humans, activation of the 
PKB/AKT/mTOR pathway has been shown to positively influence skeletal muscle mass. Most of these 
studies made use of the effects of growth hormone (GH). Systemic application of GH leads to 
increased circulating levels of IGF-1 from the liver and other tissues [14]. GH also leads to local 
synthesis of IGF-1 in the respective tissues, where it then acts in a paracrine fashion to activate mTOR 
[14]. These effects have been exploited to treat several pathologic states in humans that are 
accompanied by muscle wasting. For example, GH and/or IGF-1 have been used to treat patients with 
HIV dependent muscle wasting. Such treatment results in significant increases in lean body mass [15, 
16]. Also after severe trauma and burns, muscle protein catabolism is increased in humans [17, 18] 
and application of GH can efficiently counteract these changes [19-21].  Sarcopenia, the loss of 
muscle in the elderly, is another example for a pathologic situation in which pharmacologic GH and/or 
IGF-1 intervention could be beneficial [22]. Ageing correlates with declining secretion of GH and IGF-1 
which further emphasizes the potential usefulness of such a treatment [23, 24]. Nevertheless, it is not 
yet established whether elderly people finally profit from GH replacement [25]. The downside of GH 
substitution in patients are adverse effects, for example increased tumor growth [26]. It has been 
proposed that mainly the increase in circulating IGF-I levels upon GH substitution triggers tumor 
development and metastasis [27]. Therefore, understanding of the growth effects of non-systemic, 
locally acting IGF-1 is of profound importance and could particularly facilitate the treatment of muscle 
wasting that accompanies certain cancers. More knowledge on the tissue specific, paracrine effects of 
IGF-1 could help to “locally” activate the involved signaling pathways, while preventing systemic side 
effects.  
2.1.2. Nutrients and mTOR 
 
Next to its function in growth, mTOR has also been shown to be a cellular integrator of nutrient 
availability. Nutrients can activate mTOR directly and indirectly. In higher organisms, increases in 
systemic glucose trigger the relase of the anabolic hormone insulin from the pancreatic islets which 
activates mTOR via the insulin receptor [28, 29]. Amino acids in turn, can directly activate the kinase 
via small guanosine triphosphatases (GTPases) [30]. Withdrawal of most amino acids in cell culture 
inactivates mTOR, but withdrawal of leucine alone is as suppressive as withdrawal of all amino acids 
[31]. This suggests a primacy of leucine in regulating mTOR. Interestingly, supplementation with a 
mixture of amino acids particularly rich in leucine, counteracts age-induced muscle loss in rats. These 
effects correlate with an increased activation of mTOR in muscles of these animals [32]. Initially based 
on empirical experience, it is known for almost 30 years that branched chain amino acids (BCAA’s: 
leucine, valine and isoleucine) supplementation before and after exercise have beneficial effects on 
muscle by decreasing exercise-induced damage and promoting protein synthesis [33]. Again, BCAA 
supplementation in humans is accompanied by increased mTOR signaling [34]. 
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2.1.3. mTOR balances cellular energy generation 
 
The cellular ATP/AMP levels are sensed via the AMP-activated protein kinase (AMPK) which is an 
upstream regulator of mTOR [35]. Therefore, both nutritient avialbility and the energy status of the cell 
converge on mTOR. Consistent with a role in integrating nutrient and energy availability, mTOR 
regulates glycolytic and oxidative phosphorylation (OXPHOS) genes in a positive manner [36-40]. 
Because of its role in the regulation of OXPHOS, mTOR has also been proposed to indirectly regulate 
the cellular fatty acid content [40]. mTOR’s effects on mitochondrial function seem to be mediated by 
an interacting protein called Peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1 (PGC-
1α). PGC-1α is a transcription factor that has a key role in regulating mitochondrial function by directly 
triggering the transcription of OXPHOS genes [41]. Loss of mTOR has been shown to lower the levels 
of PGC-1α and the expression of its target genes [40]. Because of its role in facilitating mitochondrial 
function and biogenesis, PGC-1α has been proposed to be involved in adaptions to endurance 
exercise [42]. Such types of exercise can increase the mitochondrial content and therefore the 
oxidative capacity of muscle fibers. Adaptations of skeletal muscle towards a more aerobic energy 
utilization have been demonstrated to have potent beneficial effect in many diseases [43]. An increase 
in mitochondrial content is accompanied by a slower utilization of muscle glycogen and blood glucose, 
a greater reliance on fat oxidation, and lowered lactate production [44]. The above mentioned findings 
on the regulation of OXPHOS by mTOR strongly suggest that this kinase is involved in adaptations to 
exercise. Indeed, in humans the mTOR signaling pathway is responsive to acute exercise and short-
term intensified endurance training [45]. 
2.1.4. mTOR regulated autophagy 
 
mTOR has also been connected to the process of autophagy. This catabolic mechanism involves the 
import and breakdown of cytoplasmatic components into the lysosome ensuring amino acid availability 
for de novo protein synthesis and, depending on the tissue, for gluconeogenesis. The mechanism of 
autophagy has been connected to muscle wasting [46]. As discussed above, activation of mTOR can 
prevent muscle atrophy, which suggests that this effect could be mediated by inhibition of autophagic 
processes [8]. Despite of extensive research, the molecular mechanisms by which mTOR regulates 
autophagy remain to be determined [47] 
2.1.5. Bottom line on the role of mTOR in skeletal muscle 
 
Taken together, experimental evidence currently indicates that mTOR functions as a central hub that 
coordinates and integrates anabolic signals from the exterior of the muscle fibers to the cellular energy 
plants and the growth machinery. mTOR can be considered as a cellular switch that is activated by 
increased fuel, such as glucose, amino acids, and by growth factors, such as IGF-1 and insulin. Once 
in the on-state, this switch increases energy production via glycolysis and the use of mitochondria. 
Increased energy stores are a prerequisite for the subsequent building up of proteins via increased 
translation. Next to driving the whole cell into the anabolic program, mTOR also blocks catabolic 
processes, such as autophagy. It is therefore beyond question that this central role of mTOR in the cell 
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makes it a very interesting target for the development of drugs to counteract diseases that are 
accompanied by wasting and metabolic imbalance.  
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2.2. The PKB/AKT and mTOR signaling pathway 
 
One way of regulating mTOR in the postdevelopmental stage in mammals is via the PKB/AKT/IGF-1 
pathway. For example, in response to exercise, GH is released from the anterior pituitary gland into 
the circulation. As discussed under 2.1.1., GH subsequently acts on the liver and other tissues to 
cause the release of systemic insulin-like growth factor [14]. Alternatively GH and/or exercise also 
FIGURE 2. The insulin and mTOR signaling pathways. 
mTOR complex 1 mTORC1 and possibly mTORC2 respond to growth factors, energy status of the cell and 
nutrients. Activation of mTORC1 triggers translational processes and the transcription of metabolic genes, whereas 
mTORC2 acts on the cytoskeleton. 
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causes the release of a muscle tissue specific splice variant of IGF-1, the so called mechano growth 
factor (MGF) [48, 49]. Augmenting the effect of the systemic growth factors, the local, muscle released 
MGF and lGF-1 act back on the tissue in a paracrine manner. The highly anabolic hormone insulin in 
turn, is released exclusively in an endocrine manner by the pancreas in response to glucose [28]. 
Therefore, muscle growth is regulated both, locally by IGF-1 and MGF as well as systemically by GH, 
insulin and IGF-1. The insulin and the IGF receptor (Insulin-R and IGF-R) are very similar in structure 
and function. Binding of insulin or insulin-like growth factors IGFs to their receptors leads to 
recruitment and phosphorylation of the insulin receptor substrate (IRS) and activation of the PI3K 
cascade [50]. Protein kinase B (PKB), also known as AKT, is subsequently recruited to the membrane 
and becomes activated. Activation of PKB/AKT cause the membrane insertion of glucose transporter 4 
(GLUT4) which facilitates the uptake of glucose into the cell [51-53]. Activation of PKB/AKT triggers 
the inactivation of the tuberous sclerosis complex 1 (TSC1) and 2 (TSC2) to release their inhibition of 
Ras homolog enriched in brain (Rheb), which, in turn, activates mTOR [54]. Besides insulin and IGF, 
amino acids have been shown to activate the mTOR pathway via Rag proteins, a family of four related 
small guanosine triphosphatases [55]. Furthermore, TSC1/2 and mTORC1 have been shown to be 
phosphorylated by AMPK which is directly regulated by the cellular ATP content and indirectly by the 
availability of oxygen [56].  
 
In mammals, mTOR forms two distinct complexes. Activation of mTOR Complex 1 (mTORC1) leads to 
an increase in translation via activation of S6K and inhibition of the translation inhibitor 4E-BP [57]. 
Furthermore mTORC1 interacts with yin-yang 1 (YY1) and PGC-1α, which is a main transcriptional 
regulator of OXPHOS genes [58]. mTORC1 can be blocked by the immunosuppressive drug 
rapamycin. This compound inhibits the complex by acting on it via FK506-binding protein 12 
(FKBP12). Activation of mTORC2 in turn, induces phosphorylation of PKC and influences the actin 
cytoskeleton [59, 60]. mTORC2 has also been proposed to be an upstream kinase for PKB/AKT.  
 13
2.3. mTOR complex 1 and 2 
 
 
Figure 3. The mTOR 
complexes. 
In mTORC1, the mTOR 
catalytic subunit assosciates 
with raptor and mLST8 (also 
known as GβL). mTORC2 in 
contrast, contains instead of 
raptor a protein called rictor, 
but also other subunits such 
as mLST8 and mSin1. 
 
The two abovementioned distinct TOR complexes in mammals were identified from collaborating work 
of our laboratory with that of Prof. Michael N. Hall (Biozentrum, University of Basel) [59]. mTORC1 
consists of mTOR, mLST8 and raptor and is rapamycin sensitive. Raptor was identified as an mTOR 
binding partner that mediates mTOR signaling to its targets [61-63]. Raptor recruits mTOR to 
substrates, including 4E-BP1 and S6K, through their TOR signaling TOS motifs and is required for 
mTOR-mediated phosphorylation of these substrates [64-66]. It has been suggested that one possible 
mechanism for the inhibition of mTORC1 by FKBP12-rapamycin is its competition for binding with 
raptor [67]. The mTOR-raptor interaction and its regulation by nutrients and/or rapamycin is also 
dependent on mLST8 [61, 68]. More recently PRAS40 was identified to be an upstream negative 
regulator of mTORC1 [69, 70]. PRAS40 can bind to mTORC1 via raptor and seems to regulate it 
negatively by functioning as a direct inhibitor of substrate binding [69, 70].  
 
In mTORC2, which is largely rapamycin insensitive, rictor and mLST8 mediate mTOR signaling to 
downstream targets including PKCα [61]. Furthermore, the rictor-mTOR complex has been shown to 
phosphorylate PKB/AKT on Ser473 and is thus proposed to be the equivalent for PDK2, facilitating 
phosphorylation of Akt/PKB on Thr308 by PDK1 [71]. Both rictor and another component unique to 
mTORC2 called mSin1 are necessary for the phosphorylation of PKB/AKT [59, 60, 72]. mTORC2 has 
been suggested to exist in several isoforms that are defined by different splice variants of mSin1 [72]. 
Another protein, called PRR5 (Proline-rich protein 5) or protor (protein observed with rictor), was 
recently identified to bind to rictor independently of mTOR [73, 74]. PRR5/protor expression seems to 
be controlled by rictor and its loss does not significantly reduce phosphorylation of PKB/AKT at 
Ser473. Therefore, the function of the PRR5/protor-mTORC2 interaction remains to be determined. 
Furthermore, a PRR5-like protein (PRR5L) was identified to bind to mTORC2 but is not required for 
mTORC2 integrity [69]. PRR5L seems to dissociate from mTORC2 in cells with active mTOR signaling 
to induce apoptosis. Loss of PRR5L can also prevent apoptosis in mTORC2 deficient cells. Thus, 
PRR5L can be considered to be a downstream effector of mTORC2. Different from the raptor–mTOR 
association, the interaction between mTOR and rictor is not regulated by upstream signals. The 
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mechanism that induces mTORC2 kinase activity is not yet understood. However, some evidence 
suggests that TSC1/2 also regulates mTORC2 [75]. Germline disruption of mTOR and raptor in mice 
causes embryonic lethality around implantation [11, 13, 76]. Rictor knockout in contrast, leads to 
lethality in later developmental stages [12]. 
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2.4. Protein kinase B / AKT 
 
As discussed in 2.1.1. and 2.2., the mTOR upstream component PKB/AKT is a central component of 
the pathway which mediates growth of muscle fibers [8]. PKB/AKT possesses a protein domain known 
as a PH domain that can bind to phosphatidylinositol 3,4,5-trisphosphate (PtdIns3,4,5P3 or PIP3) that 
is generated by a family of enzymes called phosphoinositide 3-kinases (PI3K) [77]. Activation of a 
receptor tyrosine kinase (RTK) such as the insulin-R causes PI3K to generate elevated PIP3 levels 
which recruit PKB/AKT to the membrane. Once correctly positioned at the membrane PKB/AKT can 
then be phosphorylated by phosphoinositide dependent kinase 1 (PDK1) at threonine 308 and (PDK2) 
at serine 473 [77]. So far, at least 10 kinases have been suggested to function as PDK2. These 
include MAPK activated protein kinase 2 (MK2), integrin-linked kinase (ILK), PKC, the NIMA-related 
Figure 4. Protein kinase B or AKT 
As a consequence of PI3K activity PKB/AKT is recruited to the membrane where PDK2 phosphorylation 
stimulates the subsequent phosphorylation by PDK1. PKB/AKT can subsequently activate manifold cellular 
targets that can mediate e.g. survival, growth, proliferation, glucose uptake, metabolism, and angiogenesis. 
Activating interactions are indicated by green lines, whereas inactivating interactions are symbolized by red lines. 
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kinase-6 (NEK6), the doublestranded DNA-dependent protein kinase (DNA-PK), and the ataxia 
telangiectasia mutated gene product (ATM) [78]. Recently, mainly emphasized by the Sabatini 
laboratory, mTORC2 has been proposed to be the long-sought PDK2 [71]. Despite of that, there is 
evidence in the literature that mTORC2 is not solely required for PKB/AKT phosphorylation (see 
discussion under 2.7.) [12, 79]. 
 
Searching the literature reveals over 100 reported Akt substrates [80]. Most importantly in the context 
of mTOR signaling, PKB/AKT associates with the TSC1/2 complex, promoting phosphorylation of 
TSC2 and increased degradation which leads to the activation of mTORC1 [81-86]. Furthermore, 
PKB/AKT can phosphorylate and inhibit the mTORC1 upstream inhibitor PRAS40 [87]. Therefore, 
inactivation of mTORC1 upstream inhibitors seems to be a general mechanism of mTORC1 activation 
by PKB/AKT. Pointing out a crucial role of PKB/AKT in glucose metabolism, its activation facilitates the 
insulin-induced, AS160 (also known as TBC1 domain family member 4; TBC1D4) dependent, 
translocation of GLUT4 to the plasma membrane and inhibits glycogen synthase kinase 3 (GSK-3) 
which results in promotion of glycogen synthesis [51-53, 88]. PKB/AKT has also been shown to 
regulate cellular survival by binding and regulating Forkhead transcription factors (FOXO), Bcl-2 family 
proteins, murine double minute 2 (MDM2) and caspase-9 [89-93]. Furthermore, a crucial role of 
PKB/AKT in angiogenesis and tumor development has emerged [94]. For example, PKB/AKT directly 
activates endothelial nitric oxide (NO) synthase (eNOS) which is involved in carcinogenesis [95-97]. 
Interestingly, constitutive activation of Akt in skeletal muscle in vivo is sufficient to induce rapid skeletal 
muscle hypertrophy and loss of adipose tissue [98]. These effects correlate with a sustained activation 
of p70S6 kinase and are rapamycin sensitive which suggests an involvement of mTOR [6]. 
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2.5. The tuberous sclerosis complex 
 
Downstream of the PI3K–PKB/AKT pathway, TSC1/2 is suggested to be the primary negative 
regulator of mTORC1 signaling. In mammalian cells mTORC1-mediated phosphorylation of both S6K 
and 4E-BP1 is inhibited byTSC1/2 complex overexpression and is activated independently from 
growth factors in cells lacking the TSC1/2 complex [84, 85, 99-103]. Overexpression of a human TSC1 
transgene in mouse skeletal muscle leads to stabilized endogenous TSC2, inhibition of the mTOR 
signaling and a reduction of muscle mass [10]. Furthermore, it was demonstrated that the TSC1/2 
complex directly regulates the small GTPase Ras homolog enriched in brain Rheb which activates 
mTORC1 [104-107]. TSC2 has a GAP domain which stimulates the GTPase activity of Rheb [104, 
105]. Activation of the extracellular regulated protein kinase (ERK) and its downstream target 90 kDa 
ribosomal S6 kinase (p90rsk or RSK) can also inhibit TSC1/2 and stimulate mTORC1 activity. Growth 
stimuli that predominantly activate ERK, but not PI3K, such as the phorbol ester PMA, seem to 
modulate mTORC1 signaling trough phosphorylation of the TSC2 complex [108, 109]. Interestingly, 
also the pro-inflammatory cytokine tumor necrosis factor α (TNFα) has been found to stimulate 
mTORC1 signaling through inhibitory κB kinase β (IKKβ) which can associate with TSC1 and 
phosphorylates it [110]. As discussed before, phosphorylation of TSC2 by AMPK modulates mTORC1 
according to the status of intracellular ATP [56, 111]. AMPK inhibits mTORC1 under nutrient 
deprivation, at least in part, by phosphorylating and activating TSC2. This phosphorylation seems to 
The TSC1/2 complex 
TSC1/2 complex integrates multiple activating and inhibitory signalling pathways to regulate mTORC1 activity. 
Activating interactions are indicated by green lines, whereas inactivating interactions are symolized by red lines. 
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prime TSC2 for further phosphorylation by GSK3β [112] which is regulated downstream of PKB/AKT 
and frizzled receptors [88, 113]. Next to low ATP levels, conditions of oxygen depletion (i.e. hypoxia) 
activate the TSC1/2 complex and block mTORC1 signaling [114]. This effect is mediated indirectly via 
decreased OXPHOS resulting in low ATP levels that activate AMPK, and directly by protein regulated 
in development and DNA damage response 1 (REDD1) which seems to reverse Akt-mediated 
inhibition of TSC1/2 under hypoxic conditions [115]. In conclusion, the TSC1/2 complex modulates 
mTORC1, dependent on the presence of growth factors and inflammatory cytokines but also 
according to the cellular oxygen level and the energy status of the cell. 
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2.6. Downstream targets of mTORC1 
 
Two well known targets of mTORC1 are S6K and 4E-BP1. In response to amino acids and growth 
factors, mTORC1 activates S6K, which in turn, phosphorylates the 40S ribosomal protein S6 (S6) and 
triggers protein synthesis [116, 117]. Inactivation of S6K in mice causes muscle atrophy that is 
independent of changes in global translation, expression of E3 ubiquitin ligases and autophagy, 
suggesting the activation of an uncharacterized mediator of muscle atrophy [9, 118]. Furthermore S6K 
knockout mice are resistant against diet induced obesity [119]. Genes such as PGC1α which control 
mitochondrial function are upregulated in adipose tissue of S6K knockout mice. This is probably the 
reason for the increased mitochondrial number as well as for the upregulation of genes involved in 
uncoupling of the mitochondrial proton gradient [119]. mTORC1 also phosphorylates 4E-BP1, inducing 
its dissociation from eIF4E, which can bind the cap structure at the 5’-termini of mRNA and thereby 
facilitates cap-dependent translation [120]. Interestingly, 4E-BP1 knockout mice manifest a phenotype 
that reiterates aspects of S6K knockout mice concerning adipose tissue. Such animals contain less fat 
and increase the expression of PGC1α and of uncoupling proteins [121]. The adipose tissue 
phenotype observed in S6K and 4E-BP knockout mice seems to be similar in many aspects. This 
could be due to alterations in the levels of a circulating factor from another organ. Alternatively, S6K 
and 4E-BP could have a common or functionally redundant downstream effector in adipocytes. 
Another possibility is that loss of either S6K or 4E-BP increases the levels of mTORC1 acting on 
different substrates, for example on positive regulators of mitochondrial function such as PGC1α. 
Furthermore, it can not be excluded that loss of S6K or 4E-BP could lead to hyperactivation of the 
upstream pathway due to decreased negative feedback regulation. This, in turn, could lead to 
activation of mTOR and increased PGC1α expression and/or activity. 
 
It is known for a long time that TOR-controlled protein synthesis in yeast involves transcriptional 
regulation of genes that control ribosome biogenesis [54]. Both, in yeast and mammalian cells, 
rapamycin causes a decrease in the levels of genes involved in de novo biosynthesis of lipids and 
nucleotides, glycolysis, translation initiation and elongation, and tRNA synthesis, and an increase in 
genes involved in oxidizing amino acids and fatty acids and nucleotide salvage pathways [37, 38, 
122]. Genes involved in mitochondrial function in turn respond differently to the drug in the two 
systems. In yeast, rapamycin significantly upregulates genes required for cell respiration, while, in 
most mammalian cell lines, rapamycin down-regulates genes essential for mitochondrial function [36, 
40, 122, 123]. However, with rare exceptions, the molecular mechanisms of transcriptional regulation 
by mTOR remain largely unexplained. Interestingly, complex formation between mTOR and raptor has 
been correlated with overall mitochondrial activity [39] and, as also discussed under 2.1.3. and 2.2., a 
recent report demonstrated that mTORC1 can interact with a protein called YY1 and PGC1α, a key 
transcription factor of mitochondrial genes [40]. This study suggests that decreased mTOR activity 
inhibits an YY1–PGC1α interaction, resulting in a decreased expression of mitochondrial genes, 
including PGC1α itself. Interestingly, neither knockdown of S6K nor inhibition of PKB/AKT lowered 
PGC1α and YY1 expression in this study. 
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2.7. Downstream targets of mTORC2 
 
It has been shown in yeast that TORC2 can signal through a Rho-type GTPase on PKC which 
modulates the actin cytoskeleton [61]. Loss of rictor in some mammalian cell lines also leads to 
changes in the organization of the actin cytoskeleton [59, 60] and mTORC2 is also able to activate 
PKC in such cells [60]. PKCα is expressed in a broad range of tissues and seems to be involved in 
many cellular processes like cell growth, cell cycle control, and the regulation of cell shape and motility 
[124]. Interestingly, rictor knockout mice develop normally until day E9.5 which requires motile cells 
with an intact actin cytoskeleton [12]. This also suggests that the prenatal function of mTORC2 is only 
required late in development. As discussed under 2.4, activation of PKB/AKT requires its recruitment 
to the plasma membrane, where it is phosphorylated on Ser473 by PDK2, and on Thr308 by PDK1. In 
embryonic fibroblast derived from rictor knockout mice, phosphorylation of Ser473 is drastically 
reduced which lead to the suggestion that mTORC2 is the upstream kinase for PKB/AKT [71]. 
However, in other studies residual Ser473 phosphorylation is detected in such cells [12, 79]. This 
suggests that mTORC2 is not the only kinase required for Ser473 phosphorylation on PKB/AKT. 
Furthermore, GSK3, TSC2, mTOR, S6K and 4E-BP, which are widely accepted Akt/PKB targets, are 
not affected by the loss of functional mTORC2 [125]. Only forkhead transcription factors, namely 
FOXO1, FOXO3 and FOXO4, phosphorylation is reduced upon loss rictor. Therefore, mTORC2 
activity is only required to regulate a subset of PKB/AKT substrates [12, 71, 125, 126]. 
 
2.8. The negative feedback from S6K 
 
Chronic insulin stimulation leads to the proteasomal degradation and to downregulated transcription of 
the adaptor protein IRS-1 [127-133] due to negative feedback regulation of the insulin / PI3K signaling 
pathway. Furthermore, loss of the TSC complex results in impaired activation of PKB/AKT upon insulin 
which has been shown to be due to transcriptional repression of the IRS-1 gene [134, 135]. Next to 
transcriptional repression, the mTORC1 downstream target S6K can phosphorylate IRS-1 on specific 
residues which prevents its recruitment and binding to RTKs [134, 136]. Under some conditions, 
mTOR itself is able to phosphorylate and inhibit IRS-1 [137, 138]. In line with these findings, mTORC1 
inhibition with rapamycin can induce PKB/AKT activation in a variety of cancer cell lines [139-141]. 
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3. RESULTS 
 
3.1. Skeletal muscle-specific ablation of raptor and rictor  
To examine the function of mTORC1 and mTORC2 in skeletal muscle we used the Cre-loxP 
recombination system. To this end, we introduced loxP sites into the raptor and the rictor locus (Figure 
1A). In both cases, Cre-mediated recombination causes a frame shift and early stop of translation. In 
addition, FRT sites were inserted that flanked a neomycin resistance cassette for the selection of 
targeted embryonic stem ES cells. This cassette was removed using Flp deleter mice (Figure 1A; 
[142]). Southern blot analysis confirmed successful targeting in ES cells and germ line transmission of 
resulting chimeras (Figure 1B). Mice homozygous for the floxed allele raptorfl/fl or rictorfl/fl were mated 
with heterozygous floxed mice that also expressed Cre recombinase under the control of the muscle-
specific human skeletal actin (HSA) promoter [143]. Mice positive for the HSA-Cre transgene that also 
carried two floxed alleles were then analyzed. For simplicity, we refer to HSA-Cre; raptorfl/fl as 
RAmKO (for raptor muscle knockout) and to HSA-Cre; rictorfl/fl as RImKO (for rictor muscle knockout 
mice). Successful recombination of raptor or rictor was confirmed by PCR on genomic DNA isolated 
from tibials muscle (Figure S1A). Western blot analysis of RAmKO and RImKO skeletal muscle 
revealed a strong reduction of the respective proteins (Figure 1C; Figure S1B and Table S1). Residual 
expression of these proteins in knockout muscle is not due to leaky recombination of the targeted 
allele as raptorfl/fl or rictorfl/fl mice crossed to other Cre-expressing mice led to a complete loss of the 
respective protein in the targeted tissue (Figure S1B; [144]; M.N. Hall, personal communication). Thus, 
the low levels of raptor and rictor protein that were detected in the RAmKO and RImKO muscles are 
ascribable to the expression of raptor or rictor in non-targeted cells, such as fibroblasts, satellite cells, 
Schwann cells and peripheral nerves, which are also contained in skeletal muscle. 
 
Neither RAmKO nor RImKO mice showed an overt phenotype in the first weeks of life. Starting at the 
age of approximately 5 weeks, RAmKO mice could be distinguished from their littermates by their 
lower body weight. The difference became significant after day 63 and the mice remained lighter 
throughout life (Figure 1D). In contrast, the body weight of RImKO mice did not differ significantly from 
controls, although at higher age RImKO mice were slightly heavier (Figure 1D). For both RAmKO and 
RImKO mice, the food consumption was comparable to controls (Figure S1C and data not shown). 
RAmKO mice developed a pronounced kyphosis starting at the age of approximately 2 months and 
became markedly lean (Figure 1E; Figure S1D). In contrast, RImKO mice appeared normal. Finally, 
RAmKO mice began to die at the age of 110 days and none survived for more than 190 days (Figure 
1F). RImKO mice did not die prematurely the oldest RImKO mice now being more than 2 years old. 
 
To examine whether the difference in weight gain was based on reduced muscle mass in RAmKO 
mice, we weighed different muscles and several other organs at day 90 i.e. before the mice showed a 
severe phenotype and at day 140. As shown in Table 1, all the muscles measured were significantly 
lighter in 90 and 140 day-old RAmKO mice compared to controls. As RAmKO mice appeared lean 
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(Figure 1E) and only little or no fat was detected in older mice (Figure S1D), we also weighed the 
epididymal fat pads. Indeed, RAmKO mice contained significantly less adipose tissue at the age of 
140 days Table 1. The loss of adipose tissue does not seem to be due to changes in mitochondrial 
uncoupling properties as the body temperature of RAmKO mice was not different from control 
littermates (Figure S1E). The weight of the liver was indistinguishable from controls whereas hearts 
were again lighter Table 1. The left ventricle mass of the heart, however, correlated with the difference 
in body weight (Figure S1F), indicating that the difference in heart weight is probably due to allometric 
scaling [145]. Moreover, the ejection fraction determined by echocardiography was indistinguishable 
from littermate controls data not shown. Finally, we could not detect any recombination events in the 
hearts of RAmKO mice (Figure S1A). Our data therefore show that raptor deficiency in skeletal muscle 
causes a progressive, disproportional loss of skeletal muscle and fat. 
3.2. Deficiency of mTORC1 but not mTORC2 causes muscle dystrophy 
Kyphosis and early death are often signs of muscle dystrophy [146]. We therefore examined different 
skeletal muscles of RAmKO and RImKO mice using hematoxylin & eosin H&E staining. No change in 
the overall architecture of soleus and extensor digitorum longus EDL muscle was found in RImKO 
mice (Figure 2A). Muscles from RAmKO mice showed signs of a dystrophy, such as mononuclear 
cells (green arrowheads) and a high number of small and large muscle fibers (blue arrowheads). In 
soleus muscle and to a lower extent in EDL, we also found muscle fibers with centralized nuclei (white 
arrowheads), indicative of ongoing de- and regeneration, and structures reminiscent of central cores 
(black arrowheads in Figure 2A and Figure 2B). Quantification showed that the fiber size distribution 
was strongly altered in both soleus and EDL muscle (Figure 2C, D, E, and F). In addition, the number 
of centralized myonuclei (Figure 2G) and the relative percentage of muscle fibers with the central core-
like structures (Figure 2H) was higher in RAmKO mice compared to controls. Dystrophic hallmarks 
seemed more pronounced in soleus than in EDL muscle. Interestingly the severity of the dystrophy 
correlated with the high endogenous expression of raptor, rictor, mTOR or PKB/AKT in wild-type 
soleus muscle (Figure S2A). Muscles of RAmKO mice also showed increased immunoreactivity for 
tenascin-c and f4/80 (Figure S2B), which mark fibrotic tissue [147] and infiltrating macrophages [148], 
respectively. However, other dystrophic hallmarks including increased uptake of Evans blue into 
muscle fibers and increased levels of creatine kinase in the blood could not be detected (Figure S2C) 
and data not shown. Similarly, the number of muscle fibers was not changed in soleus muscle of 
RAmKO mice compared to controls (Figure S2D). Neuromuscular junctions of RAmKO mice were 
indistinguishable from those in control mice (Figure S2E). Probably due to ongoing de- and 
regeneration, many extrasynaptic acetylcholine receptor AChR clusters could be detected in the 
diaphragm of RAmKO mice (Figure S2F). Based on the extensive muscle wasting and the high degree 
of fibrosis, the dystrophy was particularly severe in the diaphragm of older mice (Figure 2I), suggesting 
that respiratory failure might be the cause of premature death. In contrast to RAmKO mice, muscles of 
RImKO mice did not show any alterations in fiber size (Figure S3A) and in the cytoskeletal 
organization as indicated by the sarcomeric arrangement of α-actinin (Figure S3B). In summary, our 
data show that ablation of raptor and thus of mTORC1, but not of rictor, results in a progressive 
muscle dystrophy.  
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 3.3. Skeletal muscles of RAmKO mice show alterations in their metabolic and structural 
properties 
One of the first observations we made during the course of this work was that muscles of RAmKO 
mice appeared paler than those of RImKO or control mice. This difference was particularly striking for 
the soleus muscle (Figure 3A), arrowhead and was not based on decreased vascularization, as 
revealed by staining for laminin-α5 data not shown, which is expressed in blood vessels [149]. To test 
for changes in mitochondrial function, we used an NADH-tetrazolium (NADH-TR) staining. Indeed, the 
activity of oxidative enzymes appeared lower in both, EDL and soleus muscle of RAmKO mice (Figure 
3B). Fibers with central core-like structures, which were completely devoid of NADH-TR reactivity, 
could be found in RAmKO soleus muscle (black arrowheads). Such a lack of NADH staining is a 
diagnostic feature of central core disease [150]. To further test whether the changes in NADH-TR 
reactivity involved mitochondria, we also examined longitudinal sections of soleus muscle by electron 
microscopy. Muscle of RAmKO mice was distinguishable from control muscle by a substantial loss of 
intermyofibrillar mitochondria, which are normally localized perpendicular to the Z disks arrows in 
upper panel, (Figure 3C). Only few intermyofibrillar mitochondria remained arrow lower panel, (Figure 
3C). Moreover, mitochondria localized in the subsarcolemmal space seemed more densely packed 
and swollen in RAmKO mice (Figure S4A). As a decrease in oxidative properties is often accompanied 
by a compensatory increase in glycolytic activity, we performed a periodic acid Schiff (PAS) staining. 
Indeed, the glycogen content was increased in both EDL and soleus muscle (Figure 3D). The increase 
was more pronounced in the fast-twitch EDL muscle. The glycogen content in the gastrocnemius 
muscle, which consists of a mixed population of fast- and slow-twitch fibers, was more than 5 times 
higher than in control mice (control: 21 ± 7 µmol glucose/g tissue; RAmKO: 108 ± 22 µmol glucose/g 
tissue; mean ± SEM; N = 4 mice). The change in oxidative capacity and glycogen content in skeletal 
muscle also affected overall metabolism as glucose uptake from the blood was significantly slower in 
RAmKO mice compared to littermate controls (Figure 3E).  
 
High content of glycogen is indicative of fast-twitch type II muscle fibers. To test whether muscles in 
RAmKO mice also changed their structural properties, we stained EDL and soleus muscle for the slow 
myosin heavy chain (slMHC), a marker of slow-twitch fibers. Surprisingly, EDL and soleus muscle of 
140 day-old RAmKO mice contained even more slMHC-positive muscle fibers (Figure 3F); green than 
controls and the increase of slMHC was regionalized in individual muscles (Figure S4B). In both 
muscles, the number of slMHC-positive fibers was approximately 2 to 3 times higher than in controls 
(Figure 3G & H). In soleus muscle of RAmKO mice, almost 100% of the fibers were positive for slMHC 
(Figure 3H) and this increase was also seen by Western blot analysis (Figure 3I; Table S1). Moreover, 
other components characteristic for slow-twitch muscle, such as the slow isoform of troponinT (slTnT) 
and of troponinI (slTnI), were also increased in soleus muscle of RAmKO mice (Figure 3I & J; Table 
S1). Thus, deletion of mTORC1 in skeletal muscle fibers causes a shift of their metabolic properties 
from oxidative to glycolytic. However, this change in the metabolic characteristics of muscles is 
opposite to their structural properties.  
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 3.4. Functional characterization of muscles in RAmKO mice 
To address whether the observed changes in metabolic and structural characteristics had 
consequences on the overall performance of muscle, we allowed 90 day-old mice to exercise using 
voluntary wheel running. The representative activity chart of a single mouse shows that running 
sessions of RAmKO mice were shorter and less frequent than those of controls (Figure 4A). When 
averaged over one week, the total distance run per day by RAmKO mice was ~ 60% of that of control 
mice (Figure 4B) and the top running speed was significantly lower (Figure 4C). In contrast to the 
aerobic wheel running task, RAmKO mice performed equally well as control animals in a grip strength 
test on a horizontal grid (Figure 4D). To examine the contraction properties of muscles, force 
measurements were performed on isolated EDL and soleus muscles. In line with the observed 
increase of fibers expressing structural proteins characteristic of slow-twitch muscle, time to peak, half 
time to peak and relaxation time of the twitch were all increased (Table 2). This difference to control 
mice did not reach significance in EDL muscle but was highly significant in soleus muscle (Table 2). 
Twitch force and maximal tetanic absolute force for both muscles was, however, significantly lower in 
RAmKO mice. The decrease of absolute force capacity reflects the decrease of muscle mass (Table 
1), since there is no difference of the maximal tetanic force when normalized to the muscle cross-
sectional area (Table 2). An intermittent maximal tetanic stimulation protocol revealed that both EDL 
and soleus muscle from RAmKO mice were more resistant to fatigue (Figure 4E). These data indicate 
that raptor-deficient muscle fibers have a reduced aerobic capacity voluntary wheel running like fast-
twitch, glycolytic muscle fibers, but exert contraction properties isolated muscles of slow-twitch, 
oxidative muscle fibers.  
 
3.5. Inactivation of raptor or rictor affects activation of PKB/AKT 
In search of a mechanistic explanation for the phenotypes, we examined soleus muscle of RAmKO 
and RImKO mice biochemically. In each experiment, at least three different mice were compared with 
three littermate controls. Deletion of raptor or rictor did not significantly affect the levels of mTOR 
(Figure 5A, Table S1). The levels of rictor were not lowered in RAmKO mice and there was a slight 
decrease of raptor in RImKO mice (Figure 5A, Table S1). The amount of S6K, S6 and 4EBP1, which 
are the main targets of mTORC1, was not changed in RAmKO mice. However, phosphorylation of S6 
and 4EBP1 was strongly decreased (Figure 5A; Table S1). In RImKO mice, mTORC1 targets were not 
changed but the level and activation state of PKB/AKT and PKCα, which are both well characterized 
substrates of mTORC2 [60, 71], were lower. More importantly, phosphorylation of PKB/AKT on 
residues Thr308 and Ser473 was strongly increased in RAmKO mice (Figure 5A; Table S1). 
Furthermore, the total amount of FOXO1 and FOXO3a was increased in RAmKO mice concomitant 
with an increase in phosphorylation of FOXO1 on Thr24 (Figure 5A; Table S1). In contrast, 
phosphorylation of FOXO1 on Ser316 and of FOXO3a on Thr32 was not increased.  
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Activation of S6K by mTORC1 causes feedback inhibition of the insulin/IGF-1 pathway by affecting the 
levels and the phosphorylation of IRS-1 [119, 134]. Consistent with this notion, deficiency of mTORC1 
and thus absence of S6K/S6 activation abrogated this inhibitory feedback and strongly increased IRS-
1 levels in muscles of RAmKO mice (Figure 5B; Table S1). Concomitant with the high protein levels, 
IRS phosphorylation on Ser636 and Ser639 was increased. On the other hand, both the levels and 
phosphorylation of the mitogen-activated protein kinase ERK1 and ERK2 were not significantly 
changed (Figure 5B; Table S1). Thus, activation of PKB/AKT is probably due to the failure of raptor-
deficient muscle fibers to activate S6K and thus due to the absence of the inhibitory feedback onto 
IRS. The release of this feedback in muscle may require prolonged inactivation of mTORC1 as 
phosphorylation of PKB/AKT was not increased after 8 hour treatment of cultured C2C12 myotubes 
with rapamycin and was only slightly elevated after 16 hours (Figure S5C).  
 
Next we asked whether part of the phenotype of RAmKO mice could be based on this 
hyperphosphorylation of PKB/AKT. To determine whether PKB/AKT was indeed activated within 
muscle fibers and not in non-muscle tissue of RAmKO mice; we stained cross-sections of soleus 
muscle with antibodies specific for PKB/AKT phosphorylated on Ser473 (P-PKB/AKTS473). Indeed, 
many of the muscle fibers were strongly positive for P-PKB/AKTS473 (Figure S5A). PKB/AKT has 
been shown to regulate expression of atrogenes, called atrogin-1/MAFbx and MuRF-1, via FOXO 
[151, 152]. As expected, mRNA levels for both atrogenes were significantly lower in RAmKO mice 
than in controls (Figure 5C). A further target of PKB/AKT is GSK3β, which in turn inhibits glycogen 
synthase [153]. Whereas the amount of GSK3β was unaffected, phosphorylation of Ser9 was 
significantly increased (Figure 5C; Table S1). Moreover, glycogen phosphorylase, which is the enzyme 
that generates free glucose from glycogen, was downregulated (Figure 5C; Table S1). Thus, 
hyperphosphorylation of PKB/AKT in conjunction with downregulation of glycogen phosphorylase is 
probably the basis for the increased levels of glycogen observed in RAmKO mice. 
 
In an attempt to identify the pathway that might underlie the increased number of muscle fibers 
expressing slMHC, we found a slight increase in the levels of calcineurin and a highly significant 
increase in myocyte-enhancer factor 2A (Mef2A); (Figure 5C; Table S1). A slight, but not significant 
increase in Mef2D was also observed. The increase in Mef2A is not a consequence of the ongoing de- 
and regeneration in soleus muscle as Mef2A was also increased in the least affected EDL muscle 
(Figure S5B). In contrast to skeletal muscle in vivo, Mef2A and slMHC were not increased in cultured 
C2C12 myotubes upon prolonged treatment with rapamycin (Figure S5C). 
 
3.6. Genes involved in mitochondrial biogenesis are downregulated in RAmKO mice 
One of the most striking features of RAmKO skeletal muscle is its lower oxidative capacity that is 
probably due to ultrastructural changes and loss of mitochondria. Thus, we also tested whether genes 
involved in mitochondrial biogenesis were affected by the deletion of raptor. Recent evidence indicates 
a function of mTORC1 in the regulation of mitochondrial function via PGC1α [40]. Consistent with 
these findings, transcript levels for PGC1α and for its target gene myoglobin were significantly reduced 
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in RAmKO muscle (Figure 5E). Moreover, the protein levels of the PGC1α co-activator PPARγ and the 
mitochondrial marker cytochrome c oxidase IV (COX IV) were significantly decreased in RAmKO mice 
(Figure 5F; Table S1). These results are consistent with the low oxidative capacity of muscle from 
RAmKO mice and they support the notion that this is due to loss of PGC1α.  
 
3.7. Activation of PKB/AKT is independent of mTORC2 
To test whether the hyperactivated state of PKB/AKT in RAmKO mice can be prevented by additional 
deletion of rictor, we generated double floxed mice and mated those with HSA-Cre mice. The resulting 
mice, called DmKO, lacked both raptor and rictor in skeletal muscle (Figure 5G; Table S1). Their 
overall phenotype was indistinguishable from RAmKO mice data not shown. Like in RAmKO mice, 
skeletal muscle of DmKO mice contained high levels of glycogen and was less oxidative (Figure 5H). 
Levels of mTOR were significantly lower in DmKO mice than in either of the single knockouts (Figure 
5G; Table S1). As mTORC2 was shown to phosphorylate PKB/AKT on Ser473 [71], we also tested the 
activation state of PKB/AKT in DmKO muscle. As shown in Figure 5G and in Table S1, PKB/AKT was 
still hyperphosphorylated on Thr308 and Ser473 in DmKO mice. Again, phosphorylation of PBK/Akt 
occurred only in muscle fibers and not in non-muscle tissue (Figure 5J). In summary, these results 
indicate that mTORC2 is not the only kinase that phosphorylates PKB/AKT on Ser473.  
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 4. DISCUSSION 
 
Our work dissects the role of raptor and rictor i.e. mTORC1 and mTORC2, respectively in skeletal 
muscle. The HSA-Cre mice used for our experiments start to express Cre at the earliest stages of 
skeletal muscle development when the first myotubes are formed. In fully developed muscle, Cre is 
exclusively expressed in skeletal muscle fibers but not in non-muscle cells, such as Schwann cells, 
fibroblasts or satellite cells [143]. Neither RAmKO nor RImKO mice showed any abnormalities at birth, 
indicating that mTORC1 and mTORC2 are not essential for muscle development. Whereas no overt 
phenotype was detected in RimKO mice throughout adulthood, which is consistent with another report 
[154], RAmKO mice developed a progressive dystrophy and ultimately died around the age of five 
months. Interestingly, DmKO mice showed very similar pathological changes as RAmKO mice, 
indicating that mTOR function in skeletal muscle requires only mTORC1. 
 
The dystrophy in RAmKO mice did not affect all muscles to the same extent. For example, diaphragm 
and soleus muscles were severely affected while EDL showed much less changes. Prominent 
features of the dystrophy were elevated numbers of muscle fibers with centralized nuclei and the 
presence of central core-like structures. Central cores are hallmarks of “central core diseases”, which 
are inherited neuromuscular disorders with a myopathic syndrome. The most frequent causes of this 
group of diseases are mutations in the ryanodine receptor, which is the main protein responsible for 
calcium homeostasis in muscle reviewed in [155]. Thus, the similarity of the pathology in RAmKO to 
this class of disease suggests that mishandling of intracellular calcium may underlie the disease. The 
low levels of PGC1α may additionally contribute to the dystrophic phenotype of RAmKO mice as 
conditional ablation of PGC1α in skeletal muscle results in a myopathic phenotype [156]. Finally, 
several metabolic diseases that cause accumulation of glycogen in skeletal muscle, such as Pompe’s 
and McArdle’s disease, affect skeletal muscle function. The most severely affected patients may even 
die because of respiratory distress [157]. In summary, RAmKO show changes in muscle homeostasis 
that together may lead to the progressive muscle dystrophy. 
 
4.1. Raptor is required for high oxidative capacity of skeletal muscle  
We found that the severity of the muscle dystrophy correlated with the relative levels of raptor, rictor, 
mTOR and PKB/AKT in particular muscles. Interestingly, the most affected muscles, such as soleus or 
diaphragm, are also those that are insulin-sensitive [158] and contain a high number of slow-twitch, 
oxidative fibers. Biochemical and morphological analysis showed that soleus muscle expressed little of 
the oxygen carrier myoglobin and of COXIV, and contained fewer and misshaped mitochondria. A 
direct role of mTOR and raptor for the function of mitochondria has recently been suggested using 
cultured Jurkat cells [39]. Moreover, mTOR has been shown to form a complex with PGC1α [40], 
which together with its cofactor PPARγ is a key regulator of mitochondrial biogenesis and function. 
Consistent with a regulatory function of mTORC1 for mitochondria, mRNA levels for PGC1α and 
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protein levels of PPARγ were decreased in RAmKO mice. Furthermore, mRNA and protein levels of 
target genes for PGC1α/PPARγ, such as myoglobin [58] and glycogen phosphorylase [159] were also 
reduced in RAmKO mice. Also, very similar to the phenotype of RAmKO mice, a reduced 
intermyofibrillar mitochondrial content in slow-twitch muscles has been reported in PGC1α knockout 
mice [160]. In summary, our data indicate that mTORC1 is essential for the function of mitochondria in 
skeletal muscle and they link mTORC1 to the regulation of PGC1α in vivo. 
 
4.2. Segregation of metabolic and structural properties in skeletal muscle of RAmKO mice 
Despite the loss of oxidative capacity and the downregulation of PGC1α, expression of slow structural 
proteins (slSP); (Figure 5K) was increased in RAmKO mice. Analysis of the mechanical properties in 
EDL and soleus muscle further confirmed that both muscles adapt characteristics indicative of slow-
twitch fibers. These results suggest that RAmKO mice induce a structural program for slow-twitch 
fibers. As muscle-specific inactivation of PGC1α causes a fiber-type switch to fast-contracting muscle 
fibers [161] and transgenic overexpression causes an increase in oxidative muscle [58], we also tested 
whether any other pathways that affect muscle differentiation were altered in the RAmKO mice. 
Besides PGC1α, the best characterized factors involved in fiber type determination are 
calcineurin/NFAT and the Mef2 transcription factors [162]. Of those candidate genes, the levels of 
calcineurin and in particular of Mef2A and Mef2D were increased in RAmKO mice. Thus, facilitated 
Mef2-mediated transcription may be the basis for the increased levels of slSP despite the low levels of 
PGC1α. Opposite regulation of PGC1α and Mef2A has also been seen in cultured cells when treated 
with rapamycin [40]. Mef2 has also been show to be dominant in the regulation of muscle fiber type as 
transgenic overexpression of a constitutively active form of Mef2 is sufficient to increase the number of 
slow muscle fibers [163]. Mef2 is generally thought to be controlled by calcium-activated processes 
acting via calcineurin and CaM kinase IV [164]. In this context it is interesting to note that the increase 
of the half-relaxation time in RAmKO muscles may result from a lower removal rate of calcium from 
the myoplasm by the sarcoplasmic reticulum [165]. This prolonged presence of intracellular calcium 
during contractile activity might contribute to the activation of calcium-dependent signaling pathways, 
and thus to the upregulation of slSP (Figure 5K). On the other hand, it is possible that Mef2 expression 
is increased because of hyperactivation of PKB/AKT [166]. Consistent with this notion, failure to 
induce a pronounced phosphorylation of PKB/AKT in cultured C2C12 myotubes by treatment with 
rapamycin coincided with unchanged levels of Mef2A and slMHC (Figure S5C).  
 
4.3. Raptor deficiency affects protein synthesis directly and PKB/AKT activation indirectly 
Ablation of mTORC1 in skeletal muscles prevented phosphorylation of S6K/S6 and 4EBP1. This 
branch of the mTOR signaling pathway is characterized best and has been shown to directly control 
protein synthesis. Impaired efficacy of protein synthesis in postnatal muscle might also be the reason 
for the muscles being lighter in RAmKO mice. This effect may also contribute to the shift in fiber size 
distribution towards smaller values. Our data thus implicate mTORC1 in the maintenance of mass 
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even in fully innervated muscle. Therefore, they extend previous results in which mTOR inhibition by 
rapamycin was shown to prevent compensatory hypertrophy and recovery from atrophy but not cause 
atrophy [8]. Our results are also consistent with the findings that skeletal muscles of S6K-deficient 
mice are atrophic [9]. The difference in weight of the RAmKO mice became significant only after the 
age of approximately 2 months, suggesting that the absence of raptor might be compensated for 
during early periods of muscle growth. One compensatory mechanism could be PKB/AKT-mediated 
phosphorylation of GSK3β as inhibition of GSK3β has been shown to cause hypertrophy in cultured 
C2C12 myotubes [50]. We also provide evidence that the lack of S6K activation in RAmKO mice is 
responsible for the hyperphosphorylation of PKB/AKT on Thr308 and Ser473 as levels of IRS-1 were 
highly increased. Activation of S6K has been shown to decrease the levels of IRS-1 reviewed in [167]. 
Interestingly, the same hyperactivation of PKB/AKT is seen in mice with an adipocyte-specific ablation 
of raptor [144].  
 
4.4. Raptor-deficient skeletal muscles are small, despite high energy consumption 
Whereas changes in mitochondrial content and function might be based on a direct influence of 
mTORC1 (Figure 5K), other aspects such as the loss of adipose tissue are probably a consequence of 
the hyperactivation of PKB/AKT. Muscle-specific overexpression of a constitutively active form of 
PKB/AKT causes pronounced hypertrophy [6]. Concomitantly with the hypertrophy, mice are lean and 
do not become obese on a high fat diet [6]. In the RAmKO mice, PKB/AKT was hyperactive resulting 
in mice that had much less fat than control mice on a normal chow diet Table 1 or on a high fat diet 
(KR, CFB and MAR), unpublished observation. In contrast to mice that express the constitutively 
active form of PKB/AKT, lack of mTORC1 prevented the "translation" of PKB/AKT activation into 
muscle hypertrophy in RAmKO mice, Thus, RAmKO mice behave metabolically like mice that 
overexpress activated PKB/AKT but lack the hypertrophic effect on muscle. We hypothesize that the 
metabolic phenotype of being lean is due to the high need of muscle for glucose because of their high 
glycogen storage capability and their low capacity for oxidative phosphorylation. If the muscle of 
RAmKO mice acts as such a global glucose sink, non-muscle tissues may have to use alternative 
energy sources such as fatty acids. This, in turn, could result in an increased release and mobilization 
of fatty acids from adipose tissue. The high content of glycogen is probably based on the 
hyperactivation of PKB/AKT, which inhibits GSK3β, which in turn, releases inhibition of glycogen 
synthase (Figure 5H). In addition, inhibition of GSK3β also lowers phosphorylation of NFATc and thus 
prolongs its activity in the nucleus [168]. NFATc transcription factors, which are also targets of 
calcineurin see above, are known to contribute to fiber type selection reviewed in [169]. Thus, changes 
in NFATc activity may add to the expression of structural proteins indicative of slow-twitch muscle.  
 
4.5. Hyperactivation of PKB/AKT does not require rictor/mTORC2 
Our data strongly indicate that the absence of the S6K-mediated inhibitory feedback caused 
phosphorylation of PKB/AKT on Thr308 and Ser473 in RAmKO mice. While phosphorylation on 
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Thr308 is mediated by 3-phosphoinositide-dependent kinase PDK1; [170], mTORC2 has been shown 
to phosphorylate PKB/AKT on Ser473 [71]. Consistent with such a role for mTORC2, we and others 
observed a decrease in Ser473 phosphorylation in mice deficient for rictor (Figure 5) [11, 12, 154]. We 
now show that unexpectedly, muscles from mice lacking both mTORC1 and mTORC2 still showed a 
marked increase in PKB/AKT phosphorylation on both Thr308 and Ser473. Thus, mTORC2 is not 
required to phosphorylate PKB/AKT on Ser473 in vivo, indicating that skeletal muscles express a 
PDK2 distinct from mTORC2. A candidate for this kinase is DNA-PK, which has been shown to 
phosphorylate PKB/AKT in cells that are deficient for rictor in response to DNA damage [79]. DNA-PK 
and PKB/AKT are localized in the nucleus of embryonic fibroblasts upon DNA damage [79]. However, 
PKB/AKT phosphorylated on Ser473 in DmKO mice was expressed along the sarcolemma and not 
specifically localized in myonuclei. Several additional proteins have been postulated to act as PDK2, 
some of which are expressed in skeletal muscle and are localized to the sarcolemma (see [171] for a 
review). 
 
In summary, our data show that mTORC1 is important for the function and maintenance of skeletal 
muscle. We provide evidence that the different aspects of the phenotype observed in RAmKO mice 
are probably based either on the direct effect of mTORC1 on its downstream targets S6K and 4EBP1, 
on the function of mTORC1 to regulate mitochondrial biogenesis and function via PGC1α, or on an 
indirect effect on its upstream component PKB/AKT. Our data also suggest that long-term treatment 
with high doses of rapamycin may have detrimental effects on muscle function.  
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5. EXPERIMENTAL PROCEDURES 
 
Antibodies 
 
Rabbit polyclonal antibodies: 4E-BP1 Phas-I from Zymed, ERK1&2 pan and ERK1&2 pTpY185/187 
from Biosource, FOXO1a and FOXO1a phospho S319 from Abcam, P-PKCα Ser657 and Troponin T-
SS H-55 from Santa Cruz, Phospho-4E-BP1 Ser65, PAN-actin, Akt, Phospho-Akt Thr308, Pan-
Calcineurin A, Phospho-FOXO1 Thr24/ FOXO3a Thr32, Phospho-GSK-3β Ser9, Phospho-IRS-1 
S636/639, MEF2A, mTOR, PKCα, S6 Ribosomal Protein, Phospho-S6 Ribosomal Protein Ser235/236 
and p70 S6 kinase from Cell Signaling. Rabbit monoclonal antibodies: β-actin, Phospho-Akt Ser473, 
Cox IV, FOXO3a 75D8, GSK-3β, IRS-1, PI3 Kinase p85, Raptor and Rictor from Cell Signaling and 
PPARγ from Santa Cruz. Mouse monoclonal antibodies: α-actinin and myosin skeletal, slow from 
sigma, β-tubulin and Mef2D from BD Biosciences. Goat polyclonal antibody: GP from Santa Cruz. 
 
Tissue homogenization, immunoprecipitation, SDS PAGE and Western blot 
 
Muscles frozen in liquid nitrogen were powdered on dry ice, transferred to cold RIPA buffer 
supplemented with 1% Triton-X, 10% glycerol, protease inhibitor cocktail tablets Roche and 
phosphatase inhibitor cocktail I and II Sigma. Cell lysates were incubated on ice for 2 hours, sonicated 
2 times for 15 seconds and centrifuged at 13,600g for 30 min at 4°C. Cleared lysates were then used 
to determine total protein levels BCA Protein Assay, Pierce. After dilution with sample buffer, equal 
protein amounts were loaded onto SDS gels. 
 
Histology and immunohistochemistry 
 
Muscles frozen in liquid nitrogen-cooled isopentane were fixed with 2% PFA and cut into 12 µm cross-
sections. Cross-sections were permeabilized with 1% Triton/PBS for 5 min, washed with 100 mM 
glycine/PBS for 15 min, blocked with 1% BSA/PBS for 30 min and incubated with specific primary 
antibody overnight at 4oC. Samples were subsequently washed with 1% BSA/PBS, 3 times for 1 hour, 
stained with appropriate fluorescently labeled secondary antibodies for 1 hour at room temperature. 
After washing with PBS, samples were mounted with Citifluor Citifluor Ltd. General histology on cross-
sections was performed using hematoxylin and eosin H&E; Merck, Rayway, NJ, USA. NADH staining 
was done as described [172]. Periodic acid-schiff staining PAS staining system, Sigma was performed 
according to the manufacturer's instruction. After H&E, NADH and PAS staining, samples were 
dehydrated and mounted with DePeX mounting medium Gurr, BDH. 
 
Mice 
 
PAC clones from the RPCI-21 129S6 mouse genomic DNA library [173] were identified by 
hybridization with cDNA encoding the targeted exons. For raptor, a 6.9 kb SmaI fragment spanning 2.9 
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kb upstream and 3.8 kb downstream of raptor exon 6 was isolated from clone RPCI-21 388E14 and 
cloned into pBluescript Stratagene. For the rictor targeting construct, a 10.3 kb EcoRI fragment that 
encompassed 4.5 kb upstream of exon 4 and 4.5 kb downstream of exon 5 was isolated from clone 
RPCI-21 520C16 and ligated into pBluescript. Using homologous recombination ET cloning as well as 
Cre-driven recombination in bacteria and standard cloning procedures, recombination sites, a 
selection cassette and diagnostic restriction sites were added to the vectors. The neomycin resistance 
PGK-TK-neo cassette flanked by two Frt recombination sites and a 5’-LoxP site was added 283 bp 
upstream of exon 6 in the raptor construct and 304 bp upstream of exon 4 in the rictor construct [174]. 
The 3’-LoxP sites were located 277 bp downstream of raptor exon 6 and 301 bp downstream of rictor 
exon 5, respectively. The targeting vectors were linearized and electroporated into R1 ES cells derived 
from 129S6 mice [175]. Clones were analyzed for correct integration by Southern blot analysis using 
both 5’- and 3’-probes (see Figures 1A and B). Chimeric mice were obtained by microinjection of the 
correctly targeted clones into C57BL/6 blastocysts. Chimeric mice were crossed with C57BL/6 mice to 
obtain germline transmission. Mice analyzed in this study were backcrossed to C57BL/6 for 4 
generations. The backcrosses involved mice constitutively expressing the FLP recombinase to excise 
the neomycin cassette from the targeted allele [142] and mice expressing the Cre recombinase under 
the human skeletal actin promoter [143]. As indicated in Figure 1, PCR genotyping of RAmKO mice 
was performed with primers P1: 5' ATG GTA GCA GGC ACA CTC TTC ATG and P2: 5' GCT AAA 
CAT TCA GTC CCT AAT C, resulting in an amplicon of 228 bp in case of presence of the FRT site 
and of 141 bp in case of the wild-type allele. For RImKO mice, primers P1: 5' TTA TTA ACT GTG TGT 
GGG TTG and P2: 5' CGT CTT AGT GTT GCT GTC TAG, resulting in an amplicon of 295 bp in case 
of presence of the FRT site and of 197 bp in case of a wild-type allele were used. The monoallelic 
presence of the Cre recombinase was detected using primers F: 5' TGT GGC TGA TGA TCC GAA TA 
and B: 5' GCT TGC ATG ATC TCC GGT AT resulting in an amplicon of 249 bp. Tissue-specific LoxP 
recombination in RAmKO mice was determined with primers P1 and P3: 5' CTC AGA GAA CTG CAG 
TGC TGA AGG, resulting in an amplicon of 204 bp for the recombined allele and no product for the 
wild-type or unrecombined allele (Figure 1C). LoxP recombination in RImKO mice was detected using 
primers P1 and P3: 5' CAG ATT CAA GCA TGT CCT AAG C resulting in a PCR product of 280 bp in 
presence of the recombined allele and in no product in wild-type or unrecombined allele. DmKO mice 
were genotyped with the primers used for RAmKO and RImKO mice. Brain-specific raptor and rictor 
knockout mice were obtained by crossing floxed mice with Nestin-Cre mice [176]. Mdx mice were 
obtained from the Jackson Laboratory. 
 
Animal care, body weight, food intake and body temperature measurements 
 
Mice were maintained in a conventional facility with a fixed light cycle. Studies were carried out 
according to criteria outlined for the care and use of laboratory animals and with approval of the Swiss 
authorities. Body weight, food intake and body temperature were measured weekly. A medical 
precision thermometer DM 852 from Ellab was used for the body temperature measurements. 
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Real-time PCR 
 
Total RNA was isolated SV Total RNA isolation System, Promega from soleus muscles. Reverse 
transcription was carried out using a mixture of oligodT and random hexamer primers iScript cDNA 
Synthesis Kit, Bio-Rad. Sybr Green, real-time PCR analysis Power SYBR Green Master Mix, Applied 
Biosystems was performed using the ABI Prism 7000 Sequence Detector. Expression levels for each 
gene of interest were normalized to the mean cycle number using real-time PCR for the two 
housekeeping genes β-actin and Polr2A. In all experiments, the ratio between β-actin and Polr2A was 
constant. The following primers were used: β-actin sense primer: 5' CAG CTT CTT TGC AGC TCC 
TT, antisense primer: 5' GCA GCG ATA TCG TCA TCC A; Polr2A sense primer: 5' AAT CCG CAT 
CAT GAA CAG TG, antisense primer: 5' CAG CAT GTT GGA CTC AAT GC; MAFbx sense primer: 5′ 
CTC TGT ACC ATG CCG TTC CT, antisense primer: 5′ GGC TGC TGA ACA GAT TCT CC; MuRF1 
sense primer: 5′ ACG AGA AGA AGA GCG AGC TG, antisense primer: 5′ CTT GGC ACT TGA GAG 
GAA GG; slTnI sense primer: 5’ GTG CCT GGA ACA TCC CTA AT, antisense primer: 5’ TGA GAG 
GCT GTT CTC TCT GC; PGC1α sense primer: 5' AAC GAT GAC CCT CCT CAC AC, antisense 
primer: 5' TCT GGG GTC AGA GGA AGA GA; myoglobin sense primer: 5' ATC CAG CCT CTA GCC 
CAA TC, antisense primer: 5' GAG CAT CTG CTC CAA AGT CC. 
 
In vitro muscle strength assessment 
 
EDL and soleus muscles were dissected and mounted into a muscle testing setup Heidelberg 
Scientific Instruments. Muscle force assessment was carried out as previously described [177]  
 
Voluntary wheel running 
 
Animals were individually housed in cages equipped with a running wheel carrying a magnet. Wheel 
revolutions were registered by a reed sensor connected to an I-7053D Digital-Input module Spectra, 
and the revolution counters were read by a standard laptop computer via an I-7520 RS-485-to-RS-232 
interface converter Spectra. Digitalized signals were processed by the "mouse running" software 
developed by Santhera Pharmaceuticals. 
 
Assessment of muscle fiber membrane damage 
 
Mice were forced to run downhill on a treadmill with an inclination of 15°, at the speed of 10 m/min for 
10 min. This procedure was repeated for 3 days. After the second running session, Evans blue dye 1 
mg / 0.1 ml PBS / 10 g body weight was injected intraperitoneally. Mice were sacrificed 1 hour after 
the last running session and cross-sections of the entire hindleg were analyzed [178]. 
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Glucose tolerance test 
 
60 to 65 day-old mice were fasted overnight, followed by an intraperitoneal injection of 2 g/kg glucose. 
Blood was obtained from the tail vein at the indicated time points and analyzed using a OneTouch 
UltraMini Meter Lifescan. 
 
Electron microscopy 
 
Transmission electron microscopy was performed as described [179].  
 
Tissue culture  
 
C2C12 cells were differentiated using DMEM containing 5% horse serum for 72 h before treatments 
with vehicle or rapamycin 8 or 16 h at 20 nM. 
 
Heart weight and function 
 
Under isoflurane anaesthesia, parasternal short axis M- and B-mode images of the left ventricle were 
obtained using a VisualSonics 770 machine with a 40-MHz linear transducer. Heart rate HR, left 
ventricular end-diastolic diameter LVEDD, left ventricular end-systolic diameter LVESD, diastolic and 
systolic posterior wall and septum thickness were determined. Fractional shortening %FS was 
calculated as LVEDD-LVESD/EDD x 100. Left ventricular weight was calculated from the cardiac 
dimensions obtained by the VisualSonics system and confirmed by directly weighing the wet hearts 
after sacrification of the mice. 
 
Quantifications and statistics 
 
Muscle glycogen concentration was measured in homogenates after 2 h of hydrolysis in 2N HCl at 
100°C. The resulting free glucosyl units were determined using a commercial hexokinase-based assay 
kit Sigma. For muscle fiber size quantification, pictures were collected using a Leica DM5000B 
fluorescence microscope, a digital camera F-View; Soft Imaging, and analySIS software Soft Imaging 
System. Muscle fiber size distribution was determined on laminin-γ1 immunostained muscle cross-
sections using the minimum distance of parallel tangents at opposing particle borders minimal "Feret’s 
diameter" as described elsewhere [180]. Quantification of Western blots was performed using the 
ImageJ software. Background-corrected grey values were normalized to total protein levels. Compiled 
data are expressed as mean ± SEM. For statistical comparisons of two conditions, the Student’s t- test 
was used. The level of significance is indicated as follows: *** p< 0.001, ** p< 0.01, * p< 0.05. 
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6. TABLES  
 
Table 1 90d  140d 
 ctrl RAmKO  ctrl RAmKO 
Tibia length cm 2.0 ± 0.1 2.0 ± 0.1  2.0 ± 0.1 2.1 ± 0.1 
Lower hindleg mg 449.2 ± 19.3 344.0 ± 11.4***  428.0 ± 28.0 331.6 ± 41.3** 
Triceps brachii mg 98.3 ± 11.3 67.0 ± 10.4***  89.5 ± 14.0 68.8 ± 13.8* 
Soleus mg 9.7 ± 0.8 7.4 ± 0.6***  9.2 ± 0.8 7.1 ± 1.2* 
EDL mg 12.7 ± 0.8 10.3 ± 0.7***  12.0 ± 0.7 9.4 ± 1.4* 
Tibialis anterior mg 58.3 ± 2.7 40.8 ± 2.3***  55.6 ± 1.8 39.0 ± 1.3*** 
Epididymal fat pad mg 566.4 ± 214.9 438.9 ± 93.1  616.0 ± 194.8 242.5 ± 118.7** 
Heart mg 85.12 ± 6.6 68.1 ± 4.1*  88.5 ± 2.1 72.1 ± 4.4** 
Liver mg 1350.9 ± 185.0 1187.5 ± 161.0  1232.0 ± 187.5 1055.0 ± 269.1 
* p<0.05, ** p<0.01, ***p<0.001      
 
Table 1. Analysis of particular tissues in control and RAmKO mice. Weight or length was measured for 
different muscles, bones and other organs in 90- and 140 day-old mice. P-values determined by 
Student's t-test are indicated by asterisks N = 4 mice. Values represent mean ± SD. 
 
Table 2 EDL  Sol 
 ctrl RAmKO  ctrl RAmKO 
Twitch      
Time to peak ms 10.1 ± 0.9 11.1 ± 1.2  20.3 ± 4.2 39.7 ± 2.4*** 
Half time to peak ms 3.0 ± 0.4 3.5 ± 0.5  5.6 ± 0.6 11.6 ± 1.1*** 
Half relaxation time ms 15.5 ± 2.2 16.8 ± 3.3  30.8 ± 8.7 63.0 ± 5.1*** 
Absolute force mN 54.0 ± 13.2 45.0 ± 9.7  30.0 ± 5.6 21.0 ± 8.1* 
Tetanus      
Half contraction time ms 16.6 ± 2.0 14.4 ± 1.1*  27.5 ± 5.4 41.0 ± 5.4*** 
Half relaxation time ms 22.1 ± 1.3 24.1 ± 1.6*  55.2 ± 3.9 124.4 ± 13.2*** 
Absolute force mN 311 ± 57.6 224 ± 38.1**  205 ± 20.8 164.0 ± 42.83 
Specific force mN/mm2 380.2 ± 57.2 328.3 ± 62.7  311.6 ± 56.3 264 ± 66.9 
* p<0.05, ** p<0.01, ***p<0.001 
 
Table 2. Analysis of the contractile properties of EDL and soleus muscles of control and RAmKO mice. 
Data were recorded from EDL and soleus muscles of 140 day-old mice. P-values determined by 
Student's t-test are indicated by asterisks N = 3 for RAmKO and N = 4 for control mice. Values 
represent mean ± SD. 
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7. FIGURES AND FIGURE LEGENDS 
 
 
Figure 1. Targeting strategy and initial characterization of RAmKO and RImKO mice 
(A) Schematic presentation of wild-type and targeted alleles of raptor left panel and rictor right panel 
before and after recombination. Localization and size of DNA fragments generated by particular 
restriction digests are indicated. Probes used for Southern blot analysis are shown by hatched bars. 
PCR primers for genotyping are indicated by arrows. +: wild-type allele; fl-neo: targeted allele; fl: 
alleles after recombination by FRT; -: alleles after recombination by Cre. 
 
(B) Southern blot analysis of genomic DNA from ES cells and F1 progeny of resulting chimeras. 
Correct targeting of the 5’ end is indicated by the presence of a 6.0 kb band in the raptor locus and a 
7.3 kb band in the rictor locus. Correct targeting at the 3’ end is indicated by a 6.1 kb and a 7.3 kb 
band, respectively. In each blot of ES cells, wild-type is to the left. 
 37
(C) Western blot analysis of protein extracts from skeletal muscle of RAmKO and RImKO mice. 
Controls correspond to muscle extracts from mice that carry the floxed alleles but are negative for 
HSA-Cre. Equal protein loading is confirmed by blotting for α-actinin. 
 
(D) Growth curve of RAmKO, RImKO and control mice. Mice of each genotype were weighed every 
week. A significant difference between RAmKO and control mice p<0.05 was observed after the age 
of 63 days. Individual data points represent means ± SEM N = 5 for RAmKO; N = 3 for RImKO; N = 10 
for controls. 
 
(E) Photograph of 140 day-old RAmKO, control ctrl and RImKO mice.  
 
(F) Survival curve of RAmKO , RImKO and control mice. 
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Figure 2. Muscle of RAmKO mice show signs of a progressive dystrophy 
(A) Hematoxylin & Eosin H&E staining of muscle cross-sections from the EDL and soleus Sol muscle 
of 140 day-old mice. In EDL muscle of RAmKO mice, some large blue arrowheads but also small 
fibers are present. Centralized nuclei white arrowheads and central core-like structures black 
arrowheads can be found in soleus muscle of RAmKO mice. Both muscles contain many mononuclear 
cells green arrowheads. 
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(B) Longitudinal section of soleus muscle of a 140 day-old RAmKO mouse. Besides centrally aligned 
nuclei white arrowheads, central core-like structures black arrowheads, which expand longitudinally in 
muscle fibers are visible. 
 
(C, D, E, F) Fiber size distribution in the soleus muscle of 90 day- C and 140 day-old D, and in the 
EDL muscle of 90 day- E and 140 day-old F RAmKO and control mice. 
 
(G) Mean percentage of muscle fibers with centralized nuclei cnf in the soleus and EDL muscle of 
RAmKO and control mice. 
 
(H) Percentage of muscle fibers containing central core-like structures ccls in soleus and EDL muscle 
of RAmKO and control mice. 
 
(I) H&E staining of cross-sections of the diaphragm of 90 day- and 140 day-old RAmKO and control 
mice. Individual data points and bars C – H represent mean ± SEM N=4 mice. Scale bars A, B, I = 50 
µm. P-values are: *** p< 0.001; ** p< 0.01; * p< 0.05. 
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 Figure 3. Metabolic and structural properties diverge in skeletal muscle of RAmKO mice 
(A) Preparation of the entire hindleg isolated from 90 day-old mice of the genotypes indicated. Note 
that soleus muscle arrowheads is pale in RAmKO mice compared to RImKO and control mice. 
 
(B) Activity of oxidative enzymes examined by NADH-tetrazolium staining blue precipitate in EDL and 
soleus muscle of 140 day-old mice. Central core-like structures devoid of NADH staining black 
arrowheads and increased subsarcolemmal reactivity red arrowheads was detected in some RAmKO 
soleus fibers. 
 
(C) Electron micrographs of longitudinal sections of soleus muscle from 140 day-old mice. Most 
intermyofibrillar mitochondria in RAmKO muscle are lost from their specific position next to Z disks red 
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arrows, upper panel. Remaining mitochondria in RAmKO mice show high morphologic variability red 
arrow, lower panel. 
 
(D) Periodic acid-schiff PAS staining of cross-sections from 140 day-old mice. The reaction product 
magenta color is indicative of the amount of glycogen in the tissue. 
 
(E) Glucose tolerance test with 65 day-old mice N=8 for RAmKO and N=11 for control mice.  
 
(F) Immunostaining for slow myosin heavy chain slMHC; green and the laminin γ1 chain red of cross-
section from 140 day-old mice. 
 
(G & H) Quantification of slMHC-positive muscle fibers in soleus and EDL muscle from 90- and 140 
day-old mice N = 4. 
 
(I) Western blot analysis for slMHC and slow troponin T slTnT using soleus muscle of 90 day-old mice. 
α-actinin is shown as a loading control.  
 
(J) Relative mRNA levels of the slow skeletal muscle troponin I isoform slTnI in the soleus of 90 day-
old mice as determined by QRT-PCR N = 3. Individual data points and bars E, G, H, J represent mean 
± SEM. Scale bars = 50 μm B, D, 2 μm upper pictures C, 250 nm lower pictures C and 125 µm F. P-
values are: *** p< 0.001; ** p< 0.01; * p< 0.05. 
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 Figure 4. Exercise performance and muscle physiology  
(A) Representative, activity chart with bins of 10 seconds from a single 95 day-old RAmKO or a control 
mouse. Charts were measured from 6 pm to 6 am dark cycle. 
 
(B) Average distance run per day determined during one week starting at the age of 90 days, N = 4 for 
RAmKO and N = 9 for controls. 
 
(C) Average of the top 10% speed measured over one week starting at the age of 90 days, N = 4 for 
RAmKO and N = 9 for controls. 
 
(D) Grip strength of 90 day-old RAmKO and control mice. Average time mice were able to hold on a 
horizontal grid was normalized to body weight. Values of control mice were set to 100% N = 3. 
 
 43
(E) Force capacity resistance of EDL or soleus muscle isolated from 140 day-old mice was measured 
during muscle fatigue induced by intermittent tetanic stimulation. Trains of 150 Hz tetani of 350 ms 
duration were given at 3.6 s intervals. N = 3 for RAmKO and N = 4 for control mice. Individual data 
points and bars B – E represent mean ± SEM. P-values are: *** p< 0.001; ** p< 0.01; * p< 0.05. 
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Figure 5. Biochemical characterization 
(A,B,D,F) Western blot analysis of soleus muscle from 90 day-old RAmKO, RImKO and control mice 
using antibodies directed against the proteins indicated for details see Experimental Procedures. 
Equal amount of protein was loaded in each lane. Antibodies to α-actinin and PI3K were in addition 
used as loading controls. 
 
(C & E) Relative mRNA levels of MuRF1, MAFbx, myoglobin myogl. and PGC1α in soleus muscle of 
90 day-old RAmKO or control mice. Values obtained in controls were set to 100% N = 3. 
 
(G & I) Western blot analysis of soleus muscle from 60 day-old DmKO and control mice. 
H PAS and NADH-TR staining on cross-sections of triceps muscles from 50 day-old DmKO and 
control mice.  
 
(J) Immunostaining with antibodies specific for P-PKB/AKTS473 using cross-sections of 60 day-old 
DmKO and control mice.  
 
(K) Schematic of the interactions contributing to the phenotype of RAmKO mice. Signaling pathway 
downstream of the insulin/IGF receptor is shown. Blue arrows with open arrowheads represent 
interactions that affect gene transcription; black symbols represent regulation on the protein level that 
activate or inhibit the targets. Abbreviations are: atg: atrogenes MuRF1 and MAFbx, GP: glycogen 
phosphorylase; GS: glycogen synthase; IGF-R: IGF receptor; Mb: myoglobin; slSP: slow structural 
proteins. Data C, E represent mean ± SEM. Scale bars H, J: 50 μm. P-values are: ** p< 0.01; * p< 
0.05. 
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8. SUPPLEMENTAL FIGURES 
 
 
 
Figure S1. Specificity of recombination and characterization of RAmKO mice. 
 
(A) PCR on 40 ng of genomic DNA extracted from tibialis muscle Tib. or the heart Hrt. of 60 day-old 
RAmKO, RImKO or control ctrl littermates. The PCR product indicating successful recombination by 
Cre recombinase primers P1 and P3, see Fig. 1A for details is only observed in tibialis muscle and not 
in the heart of RAmKO or RImKO mice. Note that as a result of recombination, less PCR product than 
in control mice was detected of the non-recombined locus P1-P2 primers. 
 
(B) Western blot analysis of EDL muscle from 90 day-old RImKO and control mice and with brain 
lysates isolated from mice homozygously carrying either the floxed rictor or raptor alleles and 
expressing the Cre recombinase under control of the nestin promonter Nestin-Cre. α-actinin, β-actin 
and β-tubulin were used as loading controls.  
 
(C) Average daily food intake of RAmKO and control ctrl mice between the age of 42 to 140 days N = 
5 for RAmKO; N = 8 for controls.  
 
(D) Dorsal view on a 140 day-old skinned, male RAmKO or control mouse. Hindleg muscles of the 
RAmKO mouse appear thinner and no fat pads asterisk in ctrl mouse can be detected.  
 47
(E) Basal body temperature measured at the age of 90 and 140 days does not differ between RAmKO 
and control mice N=4.  
 
(F) Left ventricular mass divided by the total body weight LV/BW does not change between 140 day-
old control and RAmKO mice N = 3 mice. Bars represent mean ± SEM. 
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Figure S2. Expression pattern and assessment of muscular dystrophy parameters in RAmKO 
mice. 
 
(A) Expression of selected proteins of the PKB/AKT and mTOR pathway in soleus and EDL muscle of 
wild-type C57/BL6 mice. Amount of total protein loaded was adjusted and additionally normalized to 
the levels of α-actinin. For quantification, grey values relative to α-actinin were measured for each 
protein and set to 100% for soleus N = 3 mice.  
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(B) Immunohistochemistry for tenascin-c and f4/80 green and DAPI staining blue reveals increased 
formation of fibrotic tissue and the presence of inflammatory monocytes white arrowheads in the 
soleus muscle of 140 day-old RAmKO mice.  
 
(C) Evans blue dye EBD incorporation in the lower hindleg of 90 day-old RAmKO and control ctrl mice 
after 3 days of forced treadmill running. No EBD positive fibers could be found in control or RAmKO 
muscles. In mdx mice, which served as an experimental control, massive incorporation of EBD was 
observed. 
 
(D) The number of fibers in the soleus of 180 day-old RAmKO mice is the same as in control 
littermates N=4.  
 
(E) Maximal intensity projection using confocal microscopy of a whole mount preparation of 
neuromuscular junctions of the diaphragm of a 90 day-old control ctrl or RAmKO mouse. Acetylcholine 
receptors AChRs were visualized by TRITC-conjugated α-bungarotoxin. There is no difference 
between the two genoytypes. 
 
(F) Low magnification pictures of diaphragms of 90 day-old mice stained with TRITC-α-bungarotoxin. 
The innervation band can be discerned at the bottom of each picture. Extrasynaptic AChR clusters 
white arrowheads are found in the diaphragm of RAmKO mice. Bars represent mean ± SEM. Scale 
bars = 50 μm B & C, 10 μm D, 100 μm E. P-value: * p< 0.05. 
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Figure S3. Fiber size distribution and cytoskeletal architecture in RImKO mice.  
 
(A) Fiber size distribution in soleus muscle of 90 day-old RImKO and control mice. There is no 
difference between the two genotypes. Data points represent mean ± SEM N = 3 mice. 
 
(B) Maximal intensity projection using confocal microscopy of muscle fibers from 90 day-old mice 
stained with antibodies to α-actinin. No difference in the sarcomeric organization was observed. Scale 
bar = 20 μm. 
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Figure S4. Subsarcolemmal accumulation of misshaped mitochondria and regionalized slMHC 
expression in RAmKO mice. 
 
(A) Representative high power electron micrographs of RAmKO and control ctrl soleus muscle. 
Subsarcolemmal mitochondria in RAmKO mice are morphologically abnormal asterisk marks a single 
mitochondrion and mitochondria are more densely packed than in control mice.  
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(B) Immunostaining for slMHC green using cross-sections of the entire hindleg of RAmKO and control 
mice. Individual muscles are outlined by red, dotted lines. A: soleus; B: plantaris-adjacent 
gastrocnemius; C: gastrocnemius; D: peroneus longus and peroneus brevis; E: extensor digitorum 
longus EDL; F: tibialis anterior. Note that the expression of slMHC in RAmKO mice is high in particular 
regions of muscles. Scale bars = 1 µm A, 200 μm B. 
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Figure S5. In-vivo and in-vitro alterations of Ser473-phosphorylated PKB/AKT, Mef2A and 
slMHC.  
 
(A) Cross-sections of the hindleg isolated from 90 day-old RAmKO or control ctrl mice were stained 
with antibodies directed against PKB/AKT phosphorylated on Ser473 P-PKB/AKTS473. Soleus muscle 
asterisk shows particularly high levels of P-PKB/AKTS473 along the sarcolemmal membrane in RAmKO 
mice. Scale bar = 125 μm. 
 
(B) Western blot analysis of EDL muscle from 90 day-old RAmKO and control ctrl mice using 
antibodies to Mef2A. Amount of total protein loaded was adjusted and SDS gels were stained with 
colloidal blue bottom as a loading control. Levels of Mef2A are increased in RAmKO compared to 
control mice.  
 
(C) Western blot analysis of C2C12 cells that were treated for either 8 or 16 hours with rapamycin. β-
tubulin was used as a loading control. As determined by quantification of grey-values N=3, treatment 
of C2C12 cells with rapamycin for eight or sixteen hours caused a significant loss of S6 
phosphorylation. A slight, non-significant increase in P-PKB/AKTS473 was observed after 16 hour 
treatment. None of the other proteins was changed.  
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9. SUPPLEMENTAL TABLE  
 RAmKO ctrl ratio number of replicates RImKO ctrl ratio 
number of 
replicates DmKO ctrl ratio 
number of 
replicates 
Raptor 11 ±3* 61 ±11 0.2 3 42 ±1* 51 ±2 0.8 3 2 ±0.5* 35 ±11 0.06 3 
mTOR 4 ±2 11 ±4 0.4 4 24 ±5 26 ±1 0.9 3 2 ±1* 17 ±5 0.1 3 
Rictor 9 ±1 8 ±1 1.2 4 26 ±1* 59 ±7 0.4 3 17 ±4* 38 ±7 0.4 4 
slMHC 42 ±0.5** 15 ±6 2.7 4         
slTnT 73 ±4*** 36 ±2 2.0 4           
S6K 56 ±5** 27 ±3 2.1 3 24 ±4 90 ±1 0.3 3     
S6 82 ±35 114 ±12 0.7 3 35 ±5 29 ±6 1.2 3 7 ±3 14 ±6 0.5 3 
P-S6S235/S236 3 ±1* 21 ±5 0.1 6 19 ±8 57 ±24 0.3 4 21 ±8 44 ±16 0.5 3 
4E-BP1 28 ±5 38 ±5 0.7 4 32 ±5 28 ±7 1.1 4     
P-4E-BP1S65 4 ±2* 16 ±2 0. 3 4 49 ±12 41 ±10 1.2 4     
PKB/ Akt  104 ±4 129 ±11 0.8 3 14 ±1 27 ±7 0.5 3 12 ±4 15 ±5 0.8 3 
P-PKB/ AktT308 9 ±3* 1 ±0.3 8 4 41 ±1* 55 ±3 0.7 3 24 ±6* 0.6 ±3 40 3 
P-PKB/ AktS473 9 ±1.5** 1 ±0.5 9.6 4 37 ±6** 98 ±11 0.4 3 22 ±5* 10 ±3 2.3 4 
PKCα 31 ±5 25 ±3 1.2 5 11 ±3*** 49 ±6 0.2 4 17 ±5 24 ±7 0.7 3 
P-PKCαS657 26 ±9 40 ±7 0.6 6 6 ±1** 58 ±11 0.1 3 48 ±17 35 ±10 1.4 3 
FOXO1 61 ±4*** 20 ±3 3.1 3 27 ±3 17 ±8 1.6 3       
P-FOXO1S316 29 ±10 37 ±7 0.8 5 62 ±5 62 ±11 1 3       
FOXO3 70 ±6*** 22 ±3 3.3 4 38 ±6 34 ±3 0.9 4       
P-FOXO1/3T24/T23 35 27 
±7*/ 
±1 
8 
28 
±2/ 
±1 
4.5/ 
1 4 
33
29
±6/ 
±7 
30
31
±2/ 
±4 
09/ 
1.1 4       
IRS-1 74 ±6*** 11 ±1 6.7 3             
P-IRS-1S636/639 41 ±14** 3 ±1 13.7 4             
ERK1/2 104 59 
±10 / 
±13 
86 
29 
±3/ 
±4 
1.2/ 
2 3             
P-ERK1/2T185/Y187 3 16 
±1.5 / 
±2 
2 
18 
±0.5/ 
±4 
2/ 
0.9 3             
GSK3β 80 ±4 69 ±4 1.2 3             
P-GSK3βS9 39 ±13* 8 ±1 4.9 3             
Glycogen phos. 15 ±7* 51 ±7 0.3 3             
Calcineurin 31 ±4 21 ±2 1.5 4             
Mef2A 126 ±12* 64 ±11 2 3             
Mef2D 36 ±3 30 ±5 1.2 4             
PPARγ 19 ±3** 41 ±3 0.5 3             
COX IV 10 ±2** 20 ±2 0.5 6             
* p<0.05, ** p<0.01, ***p<0.001 
 
 56 
 
Supplementary Table S1. Quantification of Western blot analysis for the proteins indicated. Proteins analyzed were extracted from soleus muscle of 90 day-old 
RAmKO, RImKO or control ctrl littermates. For the analysis of the DmKO mice, 60 day-old mice were compared with control littermates. Amount of total protein 
loaded onto the SDS-PAGE was adjusted and Western blots were additionally normalized with antibodies to α-actinin. Numbers given represent average grey 
values ± SEM after subtraction of the background. "Ratio" represents the average grey value obtained from a knockout animal divided by the grey values from 
the control littermates. "Number of replicates" represents the number of knockout animals analyzed. The number of control littermates was always the same or 
higher than the values given. P-values were determined by student’s t-test. 
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